Form 4: Actinium Pharmaceuticals Director Cancels Stock Options
SEC Form 4
Richard I. Steinhart, a director at Actinium Pharmaceuticals, canceled several stock options effective March 31, 2025.
Summary
- Richard I. Steinhart, a director of Actinium Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On March 31, 2025, Steinhart canceled multiple stock options to purchase shares of Actinium Pharmaceuticals' common stock.
- The cancellations were made pursuant to an Option Cancellation and Release Agreement in exchange for nominal consideration.
- The canceled options had various exercise prices ranging from $4.96 to $59.7 and expiration dates extending from April 15, 2026, to December 28, 2033.
- The total number of shares underlying the canceled options was 210,217.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a transaction. There is no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to changes in beneficial ownership by a company insider. Option cancellations can occur for various reasons, including changes in compensation agreements or the director's personal financial planning.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of earliest transaction and effective date of stock option cancellations. |
| 04/02/2025 | Date of signature on the Form 4 filing. |
| 04/15/2026 | Expiration date of one of the canceled stock option grants. |
| 03/14/2027 | Expiration date of one of the canceled stock option grants. |
| 07/13/2028 | Expiration date of one of the canceled stock option grants. |
| 07/12/2029 | Expiration date of one of the canceled stock option grants. |
| 08/12/2030 | Expiration date of one of the canceled stock option grants. |
| 09/01/2031 | Expiration date of one of the canceled stock option grants. |
| 07/01/2032 | Expiration date of one of the canceled stock option grants. |
| 12/28/2033 | Expiration date of one of the canceled stock option grants. |
Keywords
Actinium Pharmaceuticals, Richard I. Steinhart, stock options, Form 4, beneficial ownership, cancellation, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.